Terry Ferguson leads US external medical and scientific engagement for Cardiovascular at AstraZeneca. His primary responsibilities relate to strategic guidance, activity oversight, driving new initiatives and growing AstraZeneca’s internal capabilities.
Terry received his undergraduate degree (cum laude) from Harvard College in 1975 and his medical degree from the University of Pennsylvania in 1979. He did a residency in Internal Medicine at the University of Michigan in Ann Arbor, where he also spent a year as a Hypertension Fellow. He did additional subspecialty, Cardiology, training at Beth Israel Hospital and Harvard Medical School in Boston.
Following his Cardiology Fellowship, he stayed on for a year at Beth Israel and Harvard as a faculty member. In 1987, Terry joined the faculty at the Texas Heart Institute where he worked for more than 20 years, serving as the Associate Director of Cardiology Research and Co-Director of the Cardiology Fellowship program at St. Luke’s Episcopal Hospital and the Texas Heart Institute, and a faculty member at Baylor College of Medicine and The University of Texas Health Science Center.
In 2008, he left the world of academia to accept a position at The Medicines Company, and in July 2010 he joined AstraZeneca as a Senior Director in Clinical Research and as Global Brand Physician for one of AstraZeneca's key medicines. Over the ensuing years, he has served in a number of Global and US Cardiovascular roles. He is currently the Vice-President for Cardiovascular Medical and Scientific External Relations in US Medical Affairs at AstraZeneca, based in Wilmington, Delaware.
Terry Ferguson is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association. He was Editor-in-Chief of the Texas Heart Institute Journal, co-editor of Acute Coronary Syndromes and a member of the editorial board for Circulation, Cor et Vasa, Cardiology News, the Journal of Invasive Cardiology and the Journal of Interventional Cardiology. He has numerous national and international invited lectures to his credit, and has published extensively on a variety of topics in Cardiovascular Medicine.
For me, what really sets AstraZeneca apart is the culture, the company spirit, the “way-of-working”. Healthcare has changed dramatically over the last decade, and AstraZeneca has been able to evolve with the times to create a unique blend of flexibility, innovation, hard science and fun. It is not just about the job, it is about the people doing the job, and the opportunities for collaboration, creativity, development and growth.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.